Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch and Poster Display session

227P - The role of CDK4/6 inhibitors in sequencing of endocrine treatment in metastatic breast cancer or can we accept the SONIA trial results in real-world practice?

Date

16 May 2024

Session

Lunch and Poster Display session

Presenters

Olesya Stativko

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-47. 10.1016/esmoop/esmoop103200

Authors

O. Stativko1, E. Tsareva2, E. Khachaturian2, I. Shangina2, I. Pokataev2, T. Antonova2, V.N. Galkin2

Author affiliations

  • 1 GBUZ City Clinical Oncological Hospital No. 1 DZM No. 1, Moscow/RU
  • 2 Moscow City Clinical Oncological Hospital No. 1, Moscow/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 227P

Background

The recent results from SONIA trial have compromised the current standard of first-line (1L) therapy of hormone receptor-positive HER2-negative metastatic breast cancer (mBC). However, more evidence is needed to confirm the opportunity of reserving cyclin dependent kinases 4/6 inhibitors (CDKi) for second-line (2L) treatment. This strategy may help in reducing toxicity and expenditures without loss of survival benefit.

Methods

We conducted a retrospective study to compare outcomes of patients (pts) who received CDKi as 1L or 2L treatment of mBC in Moscow City Clinical Oncological Hospital No. 1 since 2020 to 2023. The primary endpoint was time to second disease progression (PFS2), defined as time from the start of 1L to progression on 2L therapy; the secondary endpoint was overall survival (OS).

Results

A total of 183 pts represented 3 treatment strategies: cohort A (n=80) received 1L endocrine monotherapy (ET) followed on progression by CDKi + ET; cohort B (n=62) -1L CDKi+ET followed by any ET (+ mTOR or PIK3CA inhibitors) and cohort C (n=41) with chemotherapy (CT) after progression on 1L CDKi + ET. Liver metastases (mts) were present in 10% and 21% in cohorts A and B+C, primary endocrine resistance – 12% and 18% in cohorts A and B+C, respectively. The median follow-up was 44 months. Median PFS2 in cohort A was 54 months which was significantly longer than in cohort B – 30 months (HR 0.3, 95% CI 0.19-0.49) and cohort C – 24 months (HR 0.23, 95% CI 0.13-0.38). The 3-year survival rates were 82%, 68% and 38% in cohorts A, B, C, respectively (HR 0.32, 95% CI 0.17-0.61). Liver mts (HR 0.76, 95% CI 0.6-0.9, p=0.027) and primary endocrine resistance (HR 0.8, 95% CI 0.6-1.0, p=0.08) were associated with poor prognosis in multivariate Cox regression model. In subgroup with liver mts mPFS2 were 25 months in cohort A versus 29 months in cohorts B+C (HR 0.35, 95% CI 0.1-1.0, p=0.05), in endocrine resistant subgroup – 22 and 35 months in cohorts A versus B+C, respectively (HR 0.4, 95% CI 0.1-1.0, p=0.07).

Conclusions

Prevalence of survival outcomes encourages the rationale of using CDKi in 2L treatment among the majority of pts including subgroups with poor prognostic factors.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.